Immunosuppressants for auto-immune diseases and pregnancy;Immunosuppresseurs utilisés dans les maladies systémiques : que faire en cas de grossesse ?

Presse Medicale

Volumn 37, Issue 11, 2008, Pages 1620-1626

  Elefant, Elisabeth ^a   Cournot, Marie Pierre ^a   Assari, Faïza ^a   Vauzelle, Catherine ^a  

^a ARMAND TROUSSEAU HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BETAMETHASONE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DEXAMETHASONE; ETANERCEPT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB;

AUTOIMMUNE DISEASE; CARCINOGENESIS; CONSULTATION; CONTRACEPTION; DIARRHEA; DRUG ELIMINATION; DRUG HALF LIFE; FETUS MATURITY; HUMAN; HYPERTENSION; KIDNEY FAILURE; LEUKOPENIA; NONHUMAN; PREGNANCY; PRENATAL CARE; PRESCRIPTION; SHORT SURVEY; TERATOGENESIS;

ABNORMALITIES, DRUG-INDUCED; AUTOIMMUNE DISEASES; CONTRACEPTION; FEMALE; FETAL DEVELOPMENT; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; RISK FACTORS;

EID: 54549085367     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2008.05.017     Document Type: Short Survey

References (28)

1. Beitins I.Z., Bayard F., Ances I.G., Kowarski A., and Migeon C.J. The transplacental passage of prednisone and prednisolone in pregnancy near term. J Pediatr 81 5 (1972) 936-945
2. Carmichael S.L., Shaw G.M., Ma C., Werler M.M., Rasmussen S.A., and Lammer E.J. Maternal corticosteroid use and orofacial clefts. Am J Obstet Gynecol 197 (2007) 585.e1-585.e7
3. Källén B. Maternal drug use and infant cleft lip/palate with special reference to corticoids. Cleft Palate Craniofac J 40 6 (2003) 624-628
4. Ng P.C., Wong G.W.K., Lam C.W.K., Lee C.H., Fok T.F., Wong M.Y., et al. Effect of multiple courses of antenatal corticosteroids on pituitary-adrenal function in preterm infants. Arch Dis Child Fetal Neonatal Ed 80 3 (1999) F213-F216
5. De Boer N.K.H., Jarbandhan S.V.A., De Graaf P., Mulder C.J.J., Van Elburg R.M., and Van Bodegraven A.A. Azathioprine use during pregnancy: unexpected intrauterine exposure to metabolites. Am J Gastroenterol 101 (2006) 1390-1392
6. Polifka J.E., and Friedman J.M. Teratogen update: azathioprine and 6-Mercaptopurine. Teratology 65 (2002) 240-261
7. Goldstein L.H., Dolinsky G., Greenberg R., Schaefer C., Cohen-Kerem R., Diav-Citrin O., et al. Pregnancy outcome of women exposed to azathioprine during pregnancy. Birth Defects Res A Clin Mol Teratol 79 (2007) 696-701
8. Langagergaard V., Pederden L., Gislum M., Norgard B., and Sorensen H.T. Birth outcome in women treated with azathioprine or mercaptopurine during pregnancy: a danish nationwide cohort study. Aliment Pharmacol Ther 25 (2007) 73-81
9. Bar Oz B., Hackman R., Einarson T., and Koren G. Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis. Transplantation 71 8 (2001) 1051-1055
10. Al-Khader A.A., Basri N., Al-Ghamdi, Shaheen, Hejaili, Flaiw, et al. Pregnancies in renal transplant recipients - with a focus on babies. Ann Transpl 9 3 (2004) 65-67
11. Bourget P., Fernandez H., Bismuth H., and Papiernik E. Transplacental passage of cyclosporine after liver transplantation. Transplantation 49 3 (1990) 663-664
12. Motta M., Ciardelli L., Marconi M., Tincani A., Gasparoni A., Lojacono A., et al. Immune system development in infants born to mothers with autoimmune disease, exposed in utero to immunosuppressive agents. Am J Perinatol 24 8 (2007) 441-447
13. Lloyd M.E., Carr M., McElhatton P., Hall G.M., and Hughes R.A. The effects of méthotrexate on pregnancy, fertility and lactation. Q J Med 92 (1999) 551-563
14. Adam M.P., Manning M.A., Beck A.E., Kwan A., Enns G.M., Clericuzio C., et al. Methotrexate/Misoprostol embryopathy: report of four cases resulting from failed medical abortion. Am J Med Genetics 123A (2003) 72-78
15. Usta I.M., Nassar A.H., Yunis K.A., and Abu-Musa A.A. Methotrexate embryopathy after therapy for misdiagnosed ectopic pregnancy. Int J Gynaecol Obstet 99 3 (2007) 253-255
16. Enns G.M., Roeder E., Chan R.T., Ali-Khan Catts Z., Cox V.A., and Golabi M. Apparent cyclophosphamide (Cytoxan) embryopathy: a distinct phenotype?. Am J Med Genetics 86 (1999) 237-241
17. Vaux K.K., Kahole N.C.O., and Lyons Jones K. Cyclophosphamide, méthotrexate, and cytarabine embropathy: is apoptosis the common pathway?. Birth Defects Res A Clin Mol Teratol 67 (2003) 403-408
18. Paladini D., Vassalo M., D'Armiento M.R., Cianciaruso B., and Martinelli P. Prenatal detection of multiple fetal anomalies following inadvertent exposure to cyclophosphamide in the first trimester of pregnancy. Birth Defects Res A Clin Mol Teratol 70 (2004) 99-100
19. Le Ray C., Coulomb A., Elefant E., Frydman R., and Audibert F. Mycophenolate mofetil in pregnancy after renal transplantation: a case of major fetal malformations. Obstet Gynecol 103 5 (2004) 1091-1094
20. Sifontis N.M., Coscia L.A., Constantinescu S., Lavelanet A.F., Moritz M.J., and Armenti V.T. Pregnancy outcomes in solid organ transplant recipients with exposure to mycophenolate mofetil or sirolimus. Transplantation 82 12 (2006) 1698-1702
21. Schoner K., Steinhard J., Figiel J., and Rehder H. Severe facial clefts in acrofacial dysostosis. Obstet Gynecol 111 (2008) 483-486
22. Perez-Aytes A., Ledo A., Boso V., Sáenz P., Roma E., Poveda J.L., et al. In utero exposure to mycophenolate mofetil: a characteristic phenotype?. Am J Med Genetics (Part A) 146A (2008) 1-7
23. Tjeertes I.F.A., Bastiaans D.E.T., Van Ganzewinkel C.J.L.M., and Zegers S.H.J. Neonatal anemia and hydrops fetalis after maternal mycophenolate mofetil use. J Perinatol 27 (2007) 62-64
24. Mahadevan U., Terdiman J.P., Church J., Vasiliauskas E., Gitis A., and Dubinsky M.C. Infliximab levels in infants born to women with inflammatory bowel disease. Gastroenterology 132 (2007) A144
25. Katz J.A. Pregnancy and inflammatory bowel disease. Curr Opin Gastroenterol 20 (2004) 328-332
26. Rosner I., Haddad A., Boulman N., Feld J., Avshovich N., Slobodin G., et al. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-alpha therapy. Rheumatology 46 9 (2007) 1508-1509
27. Friedrichs B., Tiemann M., Salwender H., Verpoort K., Wenger M.K., and Schmitz N. The effects of rituximab treatment during pregnancy on a neonate. Haematologica 91 (2006) 1426-1427
28. Decker M., Rothermundt C., Holländer G., Tichelli A., and Rochlitz C. Rituximab plus CHOP for treatment of diffuse large B-cell lymphoma during second trimester of pregnancy. Lancet Oncol 7 (2006) 693-694